Drug · CHEMBL796
METHYLPHENIDATE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. METHYLPHENIDATE. Drugs and targets, record CHEMBL796. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL796
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Open Targets' highest stage
- Approval, for 2 of its 56 diseases, from ATC, DailyMed and TTD
- Open Targets
Targets2
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| SLC6A2 | Sodium-dependent noradrenaline transporter | Norepinephrine transporter inhibitor | INHIBITOR | https://conductscience.org/library/genes/6530 |
| SLC6A3 | Sodium-dependent dopamine transporter | Dopamine transporter inhibitor | INHIBITOR | https://conductscience.org/library/genes/6531 |
Source ChEMBL
Diseases56
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| attention deficit-hyperactivity disorder | Approval | ATC, DailyMed and TTD | 194 | 181 | https://conductscience.org/library/drugs?q=MONDO_0007743 |
| Fatigue | Phase 3 | ClinicalTrials.gov | 10 | 10 | https://conductscience.org/library/drugs?q=HP_0012378 |
| cocaine dependence | Phase 2 | ClinicalTrials.gov | 6 | 6 | https://conductscience.org/library/drugs?q=MONDO_0005186 |
| Apathy | Phase 3 | ClinicalTrials.gov | 5 | 5 | https://conductscience.org/library/drugs?q=HP_0000741 |
| autism spectrum disorder | Phase 3 | ClinicalTrials.gov | 4 | 4 | https://conductscience.org/library/drugs?q=MONDO_0005258 |
| depressive disorder | Phase 2 | ClinicalTrials.gov | 4 | 4 | https://conductscience.org/library/drugs?q=MONDO_0002050 |
| multiple sclerosis symptom measurement | Phase 3 | ClinicalTrials.gov | 4 | 4 | https://conductscience.org/library/drugs?q=EFO_0803536 |
| nicotine dependence | Phase 3 | ClinicalTrials.gov | 4 | 4 | https://conductscience.org/library/drugs?q=MONDO_0008575 |
| Hyperactivity | Phase 3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=HP_0000752 |
| Parkinson disease | Phase 2 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0005180 |
1 to 10 of 56Source Open Targets
See all 56 diseasesTrials380
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more rests on that reading alone and is shown because the trial's posted result groups or NLM's indexing of its papers name the drug. 5 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00576472 | Learning Impairments Among Survivors of Childhood Cancer | Phase 4 | 469 | 2012-04-16 | methylphenidate | Its name | ClinicalTrials.gov |
| NCT02139124 | The Efficacy and Safety of PRC-063 in Adult ADHD Patients | Phase 3 | 375 | 2019-05-07 | methylphenidate | Its name | ClinicalTrials.gov |
| NCT00937040 | Adult Study / OROS Methylphenidate Hydrochloride (HCL) (OROS MPH) in Adults With Attention Deficit Hyperactivity Disorder (ADHD) | Phase 4 | 357 | 2011-08-05 | methylphenidate | Its name | ClinicalTrials.gov |
| NCT00922636 | A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder | Phase 2/3 | 340 | 2014-08-18 | methylphenidate | Its name | ClinicalTrials.gov |
| NCT00434213 | Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA | Phase 4 | 309 | 2009-03-06 | methylphenidate | Its name | ClinicalTrials.gov |
| NCT00264797 | Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents With Substance Use Disorders (SUD) | Phase 3 | 303 | 2013-06-07 | methylphenidate | Its name | ClinicalTrials.gov |
| NCT00758160 | The Impact of Osmotic Release Oral Delivery System Methylphenidate (OROS MPH) Upon Family of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD) | Phase 4 | 296 | 2014-04-08 | methylphenidate | Its name | ClinicalTrials.gov |
| NCT03618030 | PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) | Phase 3 | 288 | 2021-07-26 | methylphenidate | Its name | ClinicalTrials.gov |
| NCT00714688 | A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder | Phase 3 | 279 | 2010-04-21 | methylphenidate | Its name | ClinicalTrials.gov |
| NCT02039908 | Examining Tolerance to CNS Stimulants in ADHD | Phase 4 | 267 | 2019-09-17 | methylphenidate | Its name | ClinicalTrials.gov |
1 to 10 of 380
See all 380 trialsComparisons in its trials79
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| OROS MPH vs PLACEBO: serious adverse events | 0 of 174 | 1 of 175 | 349 | NCT00937040 | Trial comparisons |
| Methylphenidate vs Methylphenidate (Placebo): serious adverse events | 4 of 151 | 7 of 152 | 303 | NCT00264797 | Trial comparisons |
| Very Light Breakfast (VLB) Then Standard Breakfast (SB) vs Standard Breakfast (SB) Then Very Light Breakfast (VLB): serious adverse events | 0 of 148 | 0 of 149 | 297 | NCT00428792 | Trial comparisons |
| Adhansia XR vs Concerta: deaths from any cause | 0 of 133 | 1 of 134 | 267 | NCT04507204 | Trial comparisons |
| Adhansia XR vs Concerta: serious adverse events | 3 of 133 | 4 of 134 | 267 | NCT04507204 | Trial comparisons |
| Osmotic-Release Methylphenidate (OROS-MPH) vs Osmotic-Release Methylphenidate (OROS-MPH) - Placebo: serious adverse events | 2 of 127 | 0 of 128 | 255 | NCT00253747 | Trial comparisons |
| Methylphenidate Transdermal System vs Placebo (PTS): serious adverse events | 1 of 145 | 1 of 72 | 217 | NCT00499863 | Trial comparisons |
| Methylphenidate Transdermal System vs Placebo (PTS): Improvement in Parent Global Assessment (PGA) Score | 76 of 143 | 15 of 72 | 215 | NCT00499863 | Trial comparisons |
| Methylphenidate Transdermal System vs Placebo (PTS): Improvement in Clinical Global Impressions-Improvement (CGI-I) Score | 93 of 143 | 22 of 72 | 215 | NCT00499863 | Trial comparisons |
| Methylphenidate vs Placebo: deaths from any cause | 0 of 99 | 0 of 101 | 200 | NCT02346201 | Trial comparisons |
1 to 10 of 79
See all 79 comparisons in its trialsPapers from its trials356
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials63
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Continuous Performance Test | 35 | 13 | ConductCognition |
| Digit Span Test | 22 | 11 | ConductCognition |
| Stroop Color-Word Test | 11 | 7 | ConductCognition |
| 2-Back Task | 9 | 5 | ConductCognition |
| Go/No-Go Task | 8 | 5 | ConductCognition |
| 1-Back Task | 8 | 4 | ConductCognition |
| Verbal Learning | 7 | 4 | ConductCognition |
| Stop-Signal Task | 6 | 3 | ConductCognition |
| Trail Making Test A | 4 | 1 | ConductCognition |
| Trail Making Test B | 4 | 1 | ConductCognition |
1 to 10 of 63
See all 63 tests in its trialsData dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL796
GET https://conductscience.org/api/drugs/v1/CHEMBL796/diseases?page=2